Skip to main content
An official website of the United States government
Email

Prostate SPOREs

Prostate cancer (PrCa) is the most diagnosed cancer in men. In 2024, there is an estimated 299,010 new cases and 35,250 deaths for the United States. The highest incidence is found in Black men at 186.1 cases per 100,000 versus 88.6 per 100,000 in other populations averaged. The percent of patients surviving for 5 years is 97% for local and regional disease but 37% for metastatic disease.

The current PrCa SPOREs are highly collaborative translational research teams, sharing resources and conducting inter-institutional clinical studies for the prevention, monitoring, and treatment of PrCa. Translational research projects within the prostate SPOREs explore blood and urine biomarkers for risk stratification, germline genetic variants to predict aggressive cancers, the molecular evolution of resistance to androgen deprivation therapies and the development of neuroendocrine prostate cancer, and cellular mechanisms involved in metastatic PrCa. Novel therapeutics are being developed for the androgen receptor pathway inhibition, DNA damage repair and epigenetic pathways, immunotherapeutic approaches, targeting the tumor microenvironment and many other cellular pathways.

  • Reviewed:

If you would like to reproduce some or all of this content, see Reuse of NCI Information for guidance about copyright and permissions. In the case of permitted digital reproduction, please credit the National Cancer Institute as the source and link to the original NCI product using the original product's title; e.g., “Prostate SPOREs was originally published by the National Cancer Institute.”

Email